65,437 trials
HIV · Contraception
Primary: Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood — 26.6; 22.8; 16.9; 22.4 percentage of HIV target immune cells
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Alzheimer's Disease
Primary: Change From Baseline (Day 1) in Global and Regional Indices of Cerebral Metabolic Rate of Glucose (CMRglu) at Month 12 — -0.2793; -0.0887; -0.3143; -0.0786 Milligrams…
Arthritis, Juvenile
Primary: Serum Trough Concentration (C-trough) of Golimumab — 0.50 micrograms per milliliter (mcg/mL)
Mild Persistent Asthma
Primary: Post-dose PC20 Concentration After Receiving Differing Doses of Test, Reference, or Placebo — 0.608; 3.779; 4.432; 3.928 log(mg/mL) — p=<0.0001
Healthy Participants and Patients With Narcolepsy
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 1; 1; 1; 1 Participants
Chronic Fatigue Syndrome
Primary: EEG Slow Wave Activity During Sleep — 0.00002653; 0.00002257 uV^2/Hz
Neoplasms
Primary: Dose Intensity of Vemurafenib — 95.3; 92.9; 94.5 Percentage of Planned Dose
Tobacco Use Disorder
Primary: Proportion of Participants With Smoking Abstinence at 12 Months — 42; 57; 74; 104 Participants
Chronic Heart Failure
Primary: The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs) — 2 Participants
Gout
Primary: Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6 — 78.6 percentage of participants
Pre-induction Dilation of Cervix
Primary: Rate of Vaginal Delivery — 169; 159 Participants
Relapsed or Refractory Multiple Myeloma
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Knee Osteoarthritis
Primary: To Identify Imaging Markers for Characterizing the Biochemical Profiles in Synovial Fluid and Cartilage in Knee OA After HA Injection
Hemophagocytic Syndrome (HPS)
Primary: Overall Survival at 2 Months — 6 Participants